Blue Owl Capital Holdings LP Purchases Shares of 65,000 Celcuity Inc. (NASDAQ:CELC)

Blue Owl Capital Holdings LP bought a new position in Celcuity Inc. (NASDAQ:CELC) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 65,000 shares of the company’s stock, valued at approximately $1,065,000.

Several other hedge funds have also recently modified their holdings of CELC. Quest Partners LLC lifted its holdings in shares of Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after buying an additional 1,379 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Celcuity by 78.5% in the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after buying an additional 3,930 shares in the last quarter. Pale Fire Capital SE lifted its holdings in shares of Celcuity by 38.4% in the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after buying an additional 4,000 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after buying an additional 1,500 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after buying an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Trading Up 1.1 %

CELC stock opened at $14.40 on Friday. The company has a quick ratio of 14.95, a current ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity Inc. has a twelve month low of $8.39 and a twelve month high of $22.19. The stock has a market capitalization of $505.45 million, a price-to-earnings ratio of -5.18 and a beta of 0.76. The firm’s fifty day simple moving average is $16.27 and its two-hundred day simple moving average is $16.76.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. During the same quarter in the prior year, the firm posted ($0.66) EPS. As a group, analysts anticipate that Celcuity Inc. will post -2.54 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on CELC. Leerink Partners began coverage on shares of Celcuity in a research report on Monday, July 22nd. They issued an “outperform” rating and a $29.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Stifel Nicolaus reduced their price target on shares of Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Finally, Lifesci Capital began coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $28.67.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.